Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07412756 · ClinicalTrials.gov registry record · Phase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
A Phase 3 study of Depressive Disorder, Major, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT07412756: Recruiting Phase 3 study of Depressive Disorder, Major, sponsored by Eli Lilly and Company.
NCT07412756 is a Phase 3 study of Depressive Disorder, Major that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,000 participants, above the 223-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (348% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07412756, a Phase 3 study of Depressive Disorder, Major, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if depression symptoms worsen or if withdrawal from the study occurs for any reason.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brenipatide
Study Locations (20)
Florida
- Encore Medical Research - Hollywood
- K2 Medical Research - Maitland - Maitland
- Life Medical Research Group Corp - Miami Gardens
- Floridian Clinical Research, LLC - Miami Lakes
- CLA Research - Naples
- Optimal Research Sites - Orange City
- Charter Research - Orlando - Orlando
- K2 Medical Research - Tampa - Tampa
California
- Accellacare - Moorpark - Moorpark
- ATP Clinical Research - Orange
Massachusetts
- Adams Clinical Boston - Boston
- Adams Clinical Watertown - Watertown
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- CenExel iResearch, LLC - Decatur
Indiana
- Indiana University Health Neuroscience Center - Indianapolis
Iowa
- Cedar Valley Medical Specialists - Waterloo
Maryland
- Pharmasite Research, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
What NCT07412756 shows while recruiting
NCT07412756 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 223-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (348% higher).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07412756 names 20 study sites across 11 states, led by Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07412756 about?
NCT07412756 is a clinical study titled "A Study of Brenipatide in Adult Participants With Major Depressive Disorder". This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a ...
What is the current status of trial NCT07412756?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2026-02-09. Estimated completion is 2028-02.
What conditions does trial NCT07412756 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT07412756?
The interventions under investigation include: Placebo (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07412756?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07412756 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07412756's enrollment target sits among peer trials
1,000 1st of 52 higher than 52 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 3
-
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RECRUITING · Phase 3
-
Psilocybin for Major Depressive Disorder (MDD)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
ACTIVE NOT RECRUITING · Phase 3
-
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
COMPLETED · Phase 3
-
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI